Anyone who has suffered through sleepless nights due to uncontrollable itching knows that not all itching is the same. New research at Washington University School of Medicine in St. Louis explains why.
Oct 15, 2013
1
0
Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the journal Cell Reports, a team of researchers based at The Wistar Institute, ...
Sep 19, 2013
0
0
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by mutation of the gene BRAF, with regular aspirin use associated with a lower risk of BRAF-wild-type colorectal cancer ...
Jun 25, 2013
0
0
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression ...
Jun 2, 2013
0
0
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induced by the oncogene ...
May 21, 2013
0
0
Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to data presented at the ...
Apr 8, 2013
0
0
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...
Apr 8, 2013
0
0
The scientific benefits of whole genome sequencing at the Translational Genomics Research Institute (TGen) will be presented at the 14th International Myeloma Workshop, April 3-7 at the Kyoto International Conference Center.
Apr 3, 2013
0
0
Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously ...
Jan 24, 2013
0
0
Vemurafenib has been approved since February 2012 for the treatment of certain groups of adults with advanced melanoma. The drug offers major advantages in terms of survival, but also causes major side effects. Overall, there ...
Jan 8, 2013
0
0
